

Scandinavian Baltic Pancreas Club Multicenter Database

User Manual Imaging Module SBPC database

Trond Engjom, Bergen Jens Brøndum Frøkjær, Aalborg Ingfrid Salvesen Haldorsen, Bergen



A practical guide to how imaging data is to be registered

Prerequisites:

- Based on review of relevant pancreatic imaging examinations within 3 years before core module registration or during period between follow-up visits.
- Imaging findings are not solely based on information in the imaging report.
- The imaging review is **performed by a physician with adequate training**.

General comments:

- Record imaging features based on results from what you regard as the **most** accurate imaging modality first (Next slide).
- If more than one imaging modality has been employed, results from additional imaging modalities should be recorded as separate registrations.
- If you find that an imaging feature is not assessable; record as "not evaluated".
- For features that are **inherently subjective**, record it based on your **best judgement**.




Modality priority

In many patients several examinations are available.

- 1) CT closest to baseline or follow up visit has priority.
- 2) MR/EUS/US can be registered as separate contacts.


In many cases the supplementary modalities are valuable for assessment of all criteria. Results from these should be registered if available.

Pancreatic duct morphology





Scan modality



- REDCAP allows only one modality in each registration and findings should be based on either CT, MRI, transabdominal ultrasound or endoscopic ultrasound (ERCP is excluded from this list).
- If several imaging modalities have been employed prior to registration, results from additional imaging modalities should be recorded as separate registrations.




MPD caliber - definitions

- Main pancreatic duct (MPD) is considered dilated when main pancreatic duct measures: ≥4mm in the head and ≥ 3mm in the body
- Record the largest MPD diameter in the head and the body (on axial or coronal images, only transverse/perpendicular diameter)
- Measurements in millimetre (mm)

Main pancreatic duct diameter enlarged?	O NOT evaluated O No • Yes		
Main pancreatic duct diameter (HEAD)	B 5		
main paricreatic duct diameter (ncAD)	Largest diameter (mm)		
Main pancreatic duct diameter (BODY)	B 3		
Main pancreatic ouce diameter (BOD1)	Largest diameter (mm)		


MPD diameter measurements - US




Leading edge to leading edge in sonography

MPD measurement – CT with intravenous (i.v.) contrast (C)

Axial



Coronal reconstruction




MPD diameter is 5.2 mm in the pancreatic head.

MPD diameter is 4.0 mm in the pancreatic body.


MPD diameter measurement - MRI

Coronal T2-weighted



MPD diameter is 4.7 mm in the pancreatic head.

Axial T2-weighted



MPD diameter is 3.0 mm in the pancreatic body.



Irregular ducts


- MPD contour being irregular or partly ectatic.
- Ductal irregularity is best depicted in the pancreatic body and tail.
- Calliber variations >1mm are recorded as irregular ducts and graded as moderate (if 1-2mm variation) or marked (if ≥2mm).
- PS: SHOULD NOT BE CONFUSED WITH STENOSIS/OBSTRUCTION (see next ...)





2 L 0.65 cm


Irregular ducts






Irregular ducts


CT (with i.v. C)





Variable MPD diameter in the body proximal to ductal stone (causing obstruction)

MCRP




Variable MPD diameter in the pancreatic body and tail



Ductal obstruction

 Definition: Focal abrupt caliber change: Upstream dilatation and small caliber downstream.






Intraductal filling defects/ calculi

- US with echogenic structure with acoustic shadowing or CT with hyperdense structures clearly located within MPD. Can be considered in all segments.
- MRI: Abrupt filling defects at MRCP/T2 weighted-MRI.




Intraductal caliculi

US



Hyperechoic intraductal lesion (arrow) with posterior shadowing

EUS




Hyperechoic intraductal lesion (arrow) with posterior shadowing



Intraductal caliculi


CT (+ i.v. CT) – coronal reconstruction



Intraductal hyperdens caliculi in the MPD of the pancreatic body (black arrows) and head (red arrow)



MRCP




Filling defect in MBD with hypointensity (red arrow; representing calculi) and with proximal dilatation of the MPD (white arrows) which exhibits irregular contour



Dilated side ducts


- Tubular (anechoic on US) structures clearly visible and communicating with the MPD.
- Assessed typically in the pancreatic body and tail.
- If present, grade as moderate or marked.
- This feature is normally only detectable at EUS or MRCP






Dilated side ducts

EUS MRCP



Dilated side ducts (arrows) in the pancreatic body and tail

Pancreatic parenchymal morphology





Parenchymal calcifications


- CT: Hyperdens parenchymal lesions.
 - SHOULD NOT BE CONFUSED WITH VESSEL CALCIFICATIONS
- EUS/US: Echogenic structures >1 mm in length and width that produce a shadow.
- MRI is unsuited to assess calcifications: Hence state NOT evaluated
- All calcifications >1mm (numbering ≤15 calcifications in total) should be counted (If more than 15 write > 15).
- Measure the largest calcification (longest axis)






Calcifications

EUS



>15 calcifications, largest measuring 5 mm.

US




8 calcifications, largest measuring 10 mm.




Calcifications

CT (+ i.v. C) axial

coronal reconstruction







>15 calcifications, largest measuring 3mm



(Pseudo) Cysts


- EUS: Anechoic, rounded/elliptic structures that should measure >2 mm in shortest axis
- MRI: hyperintense lesion on T2/MCRP
- CT: hypodens lesion
- Count and measure largest

(Pseudo) cysts?	□ O NOT evaluated O No
Pseudocysts (number)	
Pseudocysts (largest diam)	Diameter of largest oseudocyst (mm)




(Pseudo) Cysts

CT (+ i.v. CT) axial



Hypodens cystic lesion (arrows) measuring 4.3 cm in the pancreatic tail.

MRCP



Multiple hyperintense cystic lesions (arrows) in the pancreatic head; largest measuring 3.1 cm. Note the dilated main pancreatic duct (red arrows)




Gland size

- Easiest to standardize measurements based on CT, MRI or US.
- Measure largest anteroposterior (AP) diameter in the axial plane of the pancreatic head and pancreatic body (at the level of a. mes. sup.)
- AP diameter should be perpendicular to the center axis of the pancreas






Pancreas size



Suggested AP measures by US




Measures on CT/MRI should be perpendicular to the pancreas axis





Measurements at CT (contrastenhanced axial view)




AP diameter (red line) of the pancreatic head

AP diameter (read line) of the pancreatic body perpendicular to the pancreatic axis.




Measurements at MRI

T2-weighted axial images



AP diameter (red line) of the pancreatic head in normal sized pancreas



AP diameter (red line) of the pancreatic body in normal sized pancreas



Visual and subjective criteria


- These criteria are scored in a subjective manner without strict definitions.
- All are scored as yes/no if deemed assessable.





Irregular contour

- Indistinct boundaries of the pancreas; may be focal or diffuse.
- Lobularity in EUS: Circumscribed >5 mm structures with rims hyperechoic relative to its central areas. At least 3 lobules in the body or tail. (Honeycombing: When at least 3 of the lobules are contiguous).



Lobulation and stranding (Arrows indicate boundaries of a lobe)



Focal indistinct boundary (Arrows) of the pancreatic head due to focal pancreatitis



Irregular structure

 Ranging from severe macrostructural rearrangement of the pancreas to minor features at EUS e.g. stranding, or at MRI e.g. diffuse fibrotic foci.

CT

Not including diffuse pancreatic lipomatosis



Fibrotic strands (Arrows)




Severe atrophy and irregular structure of the pancreatic body and tail (Arrows indicate pancreatic boundaries)




Continuous organ invasion

If pathological changes are observed in all segments (including the head, body and tail)

CT with i.v. contrast






Pathologic changes in all segments of the pancreas with parenchymal calcifications and atrophy of the pancreatic head, body and tail.



Focal acute pancreatitis

- Focal changes in echogenicity/density/signal and/or perfusion.
- Focal peripancreatic changes suggesting inflammation



CT with i.v. contrast:

Pathologic changes in the pancreatic tail (arrows) which is enlarged and surrounded by fatty tissue with increased density, all suggesting local inflammation due to focal pancreatitis

Scores may be retracted from the module

SBPC Database				Imaging module		
Instructions for both: Mark the <u>most recent</u> radiological examination (modality) on which the CP diagnosis is based and check the criteria that apply						
Panc	reati	c <u>ductal</u> morph	ology evaluate	d by ERCP or MRCP or EUS	3 (Cambridge classific.)	
Date of examination : (DD:MM:YYYY)						
Base	d on		□ S-MRCP	□ ERCP	□ EUS	
		Classification	Main duct	Abnormal side branches	Additional features	
	0	Normal	Normal	None		
	1	Equivocal	Normal	<3		
	2	Mild	Normal	≥3		
	3	Moderate	Abnormal *	>3		
	4	Marked	Abnormal *	>3	One or more of the following: large cavity obstruction	
* Abnormal = main pancratic duct diameter ≥ 4 mm				☐ filling defects ☐ severe dilatation		

Pancreatic parenchymal and ductal morphology (M-ANNHEIM)					
Date of examination : (DD:MM:YYYY)					
Based on ☐ CT ☐ Transabdominal ultrasound ☐ MRI/MRCP ☐ EUS					
Instr	ucti	ons:			
1. Ch	neck	mild and seven	e criteria that applies from the	list below	
2. M	atch	number of crit	eria and severity with classifica	tion	
Mild	crite	ria:		Severe criteria:	
□ M	ain p	ancreatic duct e	nlarged (between 2 and 4 mm),	☐ large cavities (>10 mm)	
🗌 sli	ght g	land enlargemer	nt (up to 2 x normal)	☐ gross gland enlargement (>2× normal)	
		geneous parencl	-	☐ intraductal filling defects or calculi	
		avities (<10 mm).	duct obstruction	
☐ irregular ducts				structure or gross irregularity	
focal acute pancreatitis				☐ contiguous organ invasion	
			of the main pancreatic duct wall		
	•egula	ar head/body co	ntour		
		Classification		Notes	
□ 0 Normal		Normal		Main pancreatic duct <2 mm, normal gland	
		INUITII		size and shape, homogenous parenchyma	
	1	Equivocal	1 mild criterion		
□ 2	0	N. ACT. 1	≥2 mild criteria		
	Mild	(+ <u>normal</u> main pancreatic duct)			
□ 3	Moderate	≥2 mild criteria	minor main pancreatic duct abnormalities:		
		(+ minor main duct abnormality)	enlargement between 2 and 4 mm		
		[- minor main doce an ini mality]	☐ increased echogenicity of the duct wall		
	4	Marked	as above + ≥ 1 severe criteri	а	

Good luck!

Recommended references:

- 1. Catalano MF, Sahai A, Levy M, Romagnuolo J, Wiersema M, Brugge W, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. GastrointestEndosc. 2009;69(7):1251-61.
- 2. Schneider A, Lohr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. JGastroenterol. 2007;42(2):101-19.
- 3. Schreyer AG, Jung M, Riemann JF, Niessen C, Pregler B, Grenacher L, et al. S3 guideline for chronic pancreatitis diagnosis, classification and therapy for the radiologist. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2014;186(11):1002-8.